Assess whether a safety signal is noise, confounding, or a real risk (136a14)

Situation

An inspector asking for batch records you cannot produce this week put 505(b)(2) literature-to-product bridge table in front of CMC change-control owner in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / Clinical and Evidence Strategy close is a safety signal is from 505(b)(2) literature-to-product bridge table, and the live options are A safety signal is noise, confounding,, A real risk.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose A safety signal is noise, confounding, / A real risk using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize A safety signal is noise, confounding, now; 505(b)(2) literature-to-product bridge table already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep A real risk in force until 505(b)(2) literature-to-product bridge table is completed after an inspector asking for batch records you cannot produce this week for CMC change-control owner.
• Treat 505(b)(2) literature-to-product bridge table as A safety signal is noise, confounding, because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page a safety signal is turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a safety signal is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move a safety signal is for CMC change-control owner.

Recommendation

Choose A safety signal is noise, confounding, / A real risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.